Sanofi announced that the U.S. District Court for the District of New Jersey ruled against Sun Pharmaceuticals in favor of Sanofi with respect to a contractual dispute arising from the resolution of the Eloxatin patent litigation. Sun appealed the District Court's April 2010 ruling requiring Sun to stop selling its at-risk generic oxaliplatin products as of June 30, 2010.

In December 2010, the U.S. Court of Appeals for the Federal Circuit vacated the District Court's ruling and remanded the case to the District Court of New Jersey for further consideration. The District Court's latest ruling maintains Eloxatin's US market exclusivity through August 9, 2012.

Sanofi said it remains committed to Eloxatin as an important therapeutic option for healthcare professionals treating patients with colorectal cancer.